drugset / Trial / NCT02495389

Mirabegron and Urinary Urgency Incontinence

NCT02495389

NaSingle-groupOpen-labelTreatment

Summary

This study is for women diagnosed with urinary urgency incontinence (UUI) or overactive bladder (OAB). Some patients continue to have symptoms even while taking medication for OAB. The purpose of this study is to estimate the number of women who respond to a medication called mirabegron and estimate change in symptom severity over 12 weeks of therapy. A secondary goal is to correlate the female urinary microbiome (FUM) with response to treatment and change in symptom severity over 12 weeks of therapy.

Timeline

Start
2015-01-28
Primary completion
2019-01-29
Completion
2019-01-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified

Indications